Baxter (BAX) Tops Q2 EPS by 5c

Baxter (NYSE: BAX) reported Q2 EPS of $1.00, ex-items, $0.05 better than the analyst estimate of $0.95. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $3.77 billion.

Baxter sees Q3 2015 EPS of $0.29-$0.31, versus the consensus of $0.27.

''The spin-off of Baxalta was a historic event for the company, and we are excited to embark on this new chapter for Baxter with a newfound focus and vision that furthers our mission to help save and sustain lives,'' said Robert L. Parkinson, Jr., chairman and chief executive officer. ''As the new Baxter evolves, we are intensely focused on accelerating profitable growth and expanding margins through disciplined portfolio management, implementation of cost reduction initiatives and the near-term launches of innovative new products. These efforts will drive meaningful value, both in the near and long terms, for our shareholders, partners, employees, and the patients and healthcare providers we serve.''

For earnings history and earnings-related data on Baxter (BAX) click here.

You May Also Be Interested In

• Brunswick (BC) Reports In-Line Q1 EPS, provides guidance
• Carrier Global (CARR) Tops Q1 EPS by 12c ; Offers Guidance
• AstraZeneca (AZN) shares jump on much stronger Q1 top and bottom line